Dyne Therapeutics (NASDAQ:DYN) Trading 11.2% Higher – Time to Buy?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price traded up 11.2% on Monday . The company traded as high as $16.58 and last traded at $16.52. 551,300 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,989,365 shares. The stock had previously closed at $14.86.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday. Wall Street Zen cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. Morgan Stanley lowered their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. Sanford C. Bernstein set a $23.00 price objective on Dyne Therapeutics in a research report on Tuesday, December 9th. Finally, Robert W. Baird set a $30.00 target price on Dyne Therapeutics in a research note on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $36.13.

Dyne Therapeutics Stock Performance

The firm’s fifty day moving average price is $17.05 and its 200-day moving average price is $17.12. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The company has a market cap of $2.83 billion, a P/E ratio of -4.84 and a beta of 1.34.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.02). As a group, research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in DYN. Aberdeen Group plc grew its position in Dyne Therapeutics by 15.0% in the third quarter. Aberdeen Group plc now owns 556,733 shares of the company’s stock valued at $7,043,000 after acquiring an additional 72,770 shares during the period. Vanguard Group Inc. boosted its stake in shares of Dyne Therapeutics by 27.6% in the 3rd quarter. Vanguard Group Inc. now owns 9,760,414 shares of the company’s stock valued at $123,469,000 after purchasing an additional 2,109,257 shares in the last quarter. Arcadia Investment Management Corp MI boosted its stake in shares of Dyne Therapeutics by 23.1% in the 2nd quarter. Arcadia Investment Management Corp MI now owns 55,215 shares of the company’s stock valued at $526,000 after purchasing an additional 10,350 shares in the last quarter. Saturn V Capital Management LP bought a new stake in shares of Dyne Therapeutics in the 2nd quarter worth about $13,856,000. Finally, Squarepoint Ops LLC increased its position in shares of Dyne Therapeutics by 334.3% during the 2nd quarter. Squarepoint Ops LLC now owns 181,740 shares of the company’s stock worth $1,730,000 after purchasing an additional 139,896 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.